Trials / Not Yet Recruiting
Not Yet RecruitingNCT06746961
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
A Single-arm, Open-label, Multicenter Phase Ⅰb/Ⅱ Clinical Study of QL1706 (bispecific Antibody Targeting PD-1 and CLTA-4) in Combination with Lenvatinib in Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Disease Progression on Immune Checkpoint Blockades Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 (bispecific antibody targeting PD-1 and CLTA-4) | 5mg/kg , iv, q3w |
| DRUG | Lenvatinib | 8 mg or 12 mg QD via oral capsule |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-07-01
- Completion
- 2027-08-01
- First posted
- 2024-12-24
- Last updated
- 2024-12-24
Source: ClinicalTrials.gov record NCT06746961. Inclusion in this directory is not an endorsement.